Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer

被引：38
作者：
Furukawa, Koichi [1 ]
Nagano, Tatsuya [1 ]
Tachihara, Motoko [1 ]
Yamamoto, Masatsugu [1 ]
Nishimura, Yoshihiro [1 ]
机构：
[1] Kobe Univ, Dept Internal Med, Div Resp Med, Grad Sch Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan
来源：
MOLECULES | 2020年 / 25卷 / 17期
关键词：
immune; checkpoint; inhibitor; programmed cell death-1 (PD-1); PD-1-ligand-1 (PD-L1); vascular endothelial growth factor (VEGF); ENDOTHELIAL GROWTH-FACTOR; REGULATORY T-CELLS; TUMOR MICROENVIRONMENT; SUPPRESSOR-CELLS; MOLECULAR-MECHANISMS; IMMUNE-RESPONSES; PD-L1; BLOCKADE; HYPOXIA; ANGIOGENESIS; VEGF;
D O I：
10.3390/molecules25173900
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems to be promising. Some phase III trials showed superiority for survival with the combination of immunotherapy and antiangiogenic therapy. In this study, we describe a synergistic mechanism of immunotherapy and antiangiogenic therapy and summarize current clinical trials of these combinations.
引用
收藏
页数：13
相关论文
共 95 条
[1]   Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study [J].
Amin, Asim ;
Plimack, Elizabeth R. ;
Ernstoff, Marc S. ;
Lewis, Lionel D. ;
Bauer, Todd M. ;
McDermott, David F. ;
Carducci, Michael ;
Kollmannsberger, Christian ;
Rini, Brian I. ;
Heng, Daniel Y. C. ;
Knox, Jennifer ;
Voss, Martin H. ;
Spratlin, Jennifer ;
Berghorn, Elmer ;
Yang, Lingfeng ;
Hammers, Hans J. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[2]   The Immunoscore: Colon Cancer and Beyond [J].
Angell, Helen K. ;
Bruni, Daniela ;
Barrett, J. Carl ;
Herbst, Ronald ;
Galon, Jerome .
CLINICAL CANCER RESEARCH, 2020, 26 (02) :332-339
[3]   Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial [J].
Atkins, Michael B. ;
Plimack, Elizabeth R. ;
Puzanov, Igor ;
Fishman, Mayer N. ;
McDermott, David F. ;
Cho, Daniel C. ;
Vaishampayan, Ulka ;
George, Saby ;
Olencki, Thomas E. ;
Tarazi, Jamal C. ;
Rosbrook, Brad ;
Fernandez, Kathrine C. ;
Lechuga, Mariajose ;
Choueiri, Toni K. .
LANCET ONCOLOGY, 2018, 19 (03) :405-415
[4]   The use of bevacizumab in pediatric retinal and choroidal disease: A review [J].
Belin, Peter J. ;
Lee, Andrew C. ;
Greaves, Giovanni ;
Kosoy, Jennifer ;
Lieberman, Ronni M. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2019, 29 (03) :338-347
[5]   LEUKOCYTE-ENDOTHELIAL CELL RECOGNITION - 3 (OR MORE) STEPS TO SPECIFICITY AND DIVERSITY [J].
BUTCHER, EC .
CELL, 1991, 67 (06) :1033-1036
[6]   Molecular mechanisms and clinical applications of angiogenesis [J].
Carmeliet, Peter ;
Jain, Rakesh K. .
NATURE, 2011, 473 (7347) :298-307
[7]   Elements of cancer immunity and the cancer-immune set point [J].
Chen, Daniel S. ;
Mellman, Ira .
NATURE, 2017, 541 (7637) :321-330
[8]   Oncology Meets Immunology: The Cancer-Immunity Cycle [J].
Chen, Daniel S. ;
Mellman, Ira .
IMMUNITY, 2013, 39 (01) :1-10
[9]   Activated STAT3 is a mediator and biomarker of VEGF endothelial activation [J].
Chen, Shao-Hua ;
Murphy, Danielle A. ;
Lassoued, Wiem ;
Thurston, Gavin ;
Feldman, Michael D. ;
Lee, William M. F. .
CANCER BIOLOGY & THERAPY, 2008, 7 (12) :1994-2003
[10]   Molecular mechanisms of blood vessel growth [J].
Conway, EM ;
Collen, D ;
Carmeliet, P .
CARDIOVASCULAR RESEARCH, 2001, 49 (03) :507-521
12345678910